Secondary Hyperparathyroidism in Children with Chronic Renal Failure: Pathogenesis and Treatment

Pediatric Drugs

Volumn 5, Issue 11, 2003, Pages 763-776

  Sanchez, Cheryl P ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; ALFACALCIDOL; ALKALINE PHOSPHATASE; ALUMINUM; BICARBONATE; CALCITRIOL; CALCIUM; CALCIUM CARBONATE; CALCIUM CHANNEL STIMULATING AGENT; CITRATE SODIUM; DOXERCALCIFEROL; ERGOCALCIFEROL DERIVATIVE; LANTHANUM; MAGNESIUM SALT; MESSENGER RNA; OXACALCITRIOL; PARATHYROID HORMONE; PARICALCITOL; PHOSPHORUS; SEVELAMER; UNCLASSIFIED DRUG; VITAMIN D; VITAMIN D DERIVATIVE;

ALKALINE PHOSPHATASE BLOOD LEVEL; ALUMINUM OVERLOAD; BONE DISEASE; BONE TURNOVER; CALCIUM ABSORPTION; CALCIUM BLOOD LEVEL; CARDIOVASCULAR RISK; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; DIALYSIS; DIET RESTRICTION; DYSLIPIDEMIA; GENE EXPRESSION; GENETIC TRANSCRIPTION; HISTOLOGY; HORMONE METABOLISM; HORMONE SYNTHESIS; HUMAN; HYPERCALCEMIA; HYPERPHOSPHATEMIA; HYPOCALCEMIA; KIDNEY FUNCTION; METABOLIC ACIDOSIS; OSTEITIS FIBROSA; PARATHYROID GLAND; PARATHYROID HYPERPLASIA; PARATHYROIDECTOMY; PATHOGENESIS; PEDIATRICS; PHOSPHATE BLOOD LEVEL; PREVALENCE; PRIORITY JOURNAL; REVIEW; SECONDARY HYPERPARATHYROIDISM; SIDE EFFECT;

CHILD; CHRONIC DISEASE; HUMANS; HYPERPARATHYROIDISM, SECONDARY; KIDNEY FAILURE;

EID: 0344442784     PISSN: 11745878     EISSN: None     Source Type: Journal    
DOI: 10.2165/00148581-200305110-00005     Document Type: Review

References (124)

1. Neu AM, Ho PLM, McDonald RA, et al. Chronic dialysis in children and adolescents: the 2001 NAPRTCS annual report. Pediatr Nephrol 2001; 17: 656-63
2. Fivush BA, Jabs K, Neu AM, et al. Chronic renal insufficiency in children and adolescents: the 1996 annual report of NAPRTCS. Pediatr Nephrol 1998; 12: 328-37
3. Hsu A, Kooh SW, Fraser D, et al. Renal osteodystrophy in children with chronic renal failure: an unexpectedly common and incapacitating complication. Pediatrics 1982; 70 (5): 742-50
4. Naveh-Many T, Rahamimov R, Livni N, et al. Parathyroid cell proliferation in normal and chronic renal failure rats. J Clin Invest 1995; 96: 1786-93
5. Denda M, Finch J, Slatopolsky E. Phosphorus accelerates the development of parathyroid hyperplasia and secondary hyperparathyroidism in rats with renal failure. Am J Kidney Dis 1996; 28 (4): 596-602
6. Slatopolsky E, Delmez JA. Pathogenesis of secondary hyperparathyroidism. Am J Kidney Dis 1994; 23 (2): 229-36
7. Moallem E, Kilav R, Silver J, et al. RNA-protein binding and post-transcriptional regulation of parathyroid hormone gene expression by calcium and phosphate. J Biol Chem 1998; 273 (9): 5253-9
8. Slatopolsky E, Finch J, Denda M, et al. Phosphorus restriction prevents parathyroid gland growth. J Clin Invest 1996; 97: 2534-40
9. Almaden Y, Canalejo A, Ballesteros E, et al. Effect of high extracellular phosphate concentration on arachidonic acid production by parathyroid tissue in vitro. J Am Soc Nephrol 2000; 11 (9): 1712-8
10. Estepa JC, Aguilera-Tejero E, Lopez I, et al. Effect of phosphate on parathyroid hormone secretion in vivo. J Bone Miner Res 1999; 14: 1848-54
11. Tatsumi S, Segawa H, Morita K, et al. Molecular cloning and hormonal regulation of pit-1, a sodium-dependent phosphate cotransporter from rat parathyroid glands. Endocrinology 1998; 139 (4): 1692-9
12. Block G, Port F. Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: recommendations for a change in management. Am J Kidney Dis 2000; 35 (6): 1226-37
13. 4 product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol 2001; 12 (10): 2131-8
14. Portale AA, Booth BE, Halloran BP, et al. Effect of dietary phosphorus on circulating concentrations of 1,25-dihydroxyvitamin and immunoreactive parathyroid hormone in children with moderate renal insufficiency. J Clin Invest 1984; 73: 1580-9
15. Lopez-Hilker S, Dusso AS, Rapp NS, et al. Phosphorus restriction reverses hyperparathyroidism in uremia independent of changes in calcium and calcitriol. Am J Physiol 1990; 28: F432-7
16. Martinez I, Saracho R, Montenegro J, et al. A deficit of calcitriol synthesis may not be the initial factor in the pathogenesis of secondary hyperparathyroidism. Nephrol Dial Transplant 1996; 11 Suppl. 3: 22-8
17. Portale AA, Booth BE, Tsai HC, et al. Reduced plasma concentration of 1,25-dihydroxyvitamin D in children with moderate renal insufficiency. Kidney Int 1982; 21: 627-32
18. 3 in the parathyroid glands of patients with renal failure. N Engl J Med 1987; 316 (25): 1573-7
19. Pitts TO, Piraino BH, Mitro R, et al. Hyperparathyroidism and 1,25-dihydroxyvitamin D deficiency in mild, moderate, and severe renal failure. J Clin Endocrinol Metab 1988; 67 (5): 876-81
20. Malluche HH, Ritz E, Lange HP, et al. Bone histology in incipient and advanced renal failure. Kidney Int 1976; 9: 355-62
21. Malluche HH, Faugere M-C. Renal bone disease 1990: an unmet challenge for the nephrologist. Kidney Int 1990; 38: 193-211
22. Norman AW. Bone biochemistry and physiology from the perspectives of the vitamin D endocrine system. Curr Opin Rheumatol 1992; 4: 375-82
23. 3 receptor density is associated with a more severe form of parathyroid hyperplasia in chronic uremic patients. J Clin Invest 1993; 92: 1436-43
24. 2+-sensing receptor from bovine parathyroid. Nature 1993; 366: 575-80
25. Brown EM, Wilson RE, Eastman RC, et al. Abnormal regulation of parathyroid hormone release by calcium in secondary hyperparathyroidism due to chronic renal failure. J Clin Endocrinol Metab 1982; 54 (1): 172-9
26. Ramirez JA, Goodman WG, Gornbein J, et al. Direct in vivo comparison of calcium-regulated parathyroid hormone secretion in normal volunteers and patients with secondary hyperparathyroidism. J Clin Endocrinol Metab 1993; 76 (6): 1489-94
27. Messa P, Vallone C, Mioni G, et al. Direct in vivo assessment of parathyroid hormone-calcium relationship curve in renal patients. Kidney Int 1994; 46: 1713-20
28. Yano S, Sugimoto T, Tsukamoto T, et al. Association of decreased calcium-sensing receptor expression with proliferation of parathyroid cells in secondary hyperparathyroidism. Kidney Int 2000; 58: 1980-6
29. Ritter CS, Martin DR, Lu Y, et al. Reversal of secondary hyperparathyroidism by phosphate restriction restores parathyroid calcium-sensing receptor expression and function. J Bone Miner Res 2002; 17 (12): 2206-13
30. Salusky IB, Ramirez JA, Oppenheim W, et al. Biochemical markers of renal osteodystrophy in pediatric patients undergoing CAPD/CCPD. Kidney Int 1994; 45: 253-8
31. Quarles LD, Lobaugh B, Murphy G. Intact parathyroid hormone overestimates the presence and severity of parathyroid-mediated osseous abnormalities in uremia. J Clin Endocrinol Metab 1992; 75: 145-50
32. Slatopolsky E, Finch J, Clay P, et al. A novel mechanism for skeletal resistance in uremia. Kidney Int 2000; 58 (2): 753-61
33. John MR, Goodman WG, Gao P, et al. A novel immunoradiometric assay detects full-length human PTH but not amino-terminally truncated fragments: implications for PTH measurements in renal failure. J Clin Endocrinol Metab 1999; 84 (11): 4287-90
34. Coen G, Bonucci E, Ballanti P, et al. PTH 1 -84 and PTH "7-84" in the noninvasive diagnosis of renal bone disease. Am J Kidney Dis 2002; 40 (2): 348-54
35. Salusky IB, Goodman WG, Kuizon BD, et al. Similar predictive value of bone turnover using the first-and second-generation immunometric PTH assays in pediatric patients treated with peritoneal dialysis. Kidney Int 2003; 63: 1801-8
36. Reichel H, Esser A, Roth H-J, et al. Influence of PTH assay methodology on differential diagnosis of renal bone disease. Nephrol Dial Transplant 2003; 18 (4): 759-68
37. Salusky IB. Bone and mineral metabolism in childhood end-stage renal disease. Pediatric Clinics of North America. Vol. 42. Philadelphia (PA); W.B. Saunders/ Elsevier Science, 1995: 1531-50
38. Monier-Faugere M-C, Geng Z, Mawad H, et al. Improved assessment of bone turnover by the PTH (1-84)/large C-PTH fragments ratio in ESRD patients. Kidney Int 2001; 60 (4): 1460-8
39. Salem M, Sanchez C, Kuizon B, et al. Renal bone diseases in children with chronic renal failure [abstract]. J Am Soc Nephrol 1998; 9: 549A
40. Hamdy NAT, Kanis JA, Beneton MNC, et al. Effect of alfacalcidol on natural course of renal bone disease in mild to moderate renal failure. BMJ 1995; 310: 358-61
41. Sanchez CP, Salusky IB, Kuizon BD, et al. Growth of long bones in renal failure: roles of hyperparathyroidism, growth hormone and calcitriol. Kidney Int 1998; 54 (6): 1879-87
42. Mehls O, Ritz E, Gilli G, et al. Skeletal changes and growth in experimental uremia. Nephron 1977; 18: 288-300
43. Hanna JD, Santos F, Foreman JW, et al. Insulin-like growth factor-I gene expression in the tibial epiphyseal growth plate of growth hormone-treated uremic rats. Kidney Int 1995; 47: 1374-82
44. Urena P, Ferreira A, Morieux C, et al. PTH/PTHrP receptor mRNA is down-regulated in epiphyseal cartilage growth plate of uremic rats. Nephrol Dial Transplant 1996; 11: 2008-16
45. Cobo A, Carbajo E, Santos F, et al. Morphometry of uremic rat growth plate. Miner Electrolyte Metab 1996; 22: 192-5
46. Langub MC, Monier-Faugere M-C, Wang G. et al. Administration of PTH-(7-84) antagonizes the effects of PTH-(1-84) on bone in rats with moderate renal failure. Endocrinology 2003; 144 (4): 1135-8
47. Graham KA, Hoenich NA, Tarbit M, et al. Correction of acidosis in hemodialysis patients increases the sensitivity of the parathyroid glands to calcium. J Am Soc Nephrol 1997; 8(4): 627-31
48. Bushinsky DA. Net calcium efflux from live bone during chronic metabolic, but not respiratory acidosis. Am J Physiol 1989; 265: 836-42
49. Barsotti G, Lazzeri M, Cristofano C, et al. The role of metabolic acidosis in causing uremic hyperphosphatemia. Miner Electrolyte Metab 1986; 12: 103-6
50. Movilli E, Zani R, Carli O, et al. Direct effect of the correction of acidosis on plasma parathyroid hormone concentrations, calcium and phosphate in hemodialysis patients: a prospective study. Nephron 2001; 87 (3): 257-62
51. 3 levels in chronic renal failure. Miner Electrolyte Metab 1995; 21 (6): 398-402
52. Carbajo E, Lopez JM, Santos F, et al. Histologic and dynamic changes induced by chronic metabolic acidosis in the rat growth plate. J Am Soc Nephrol 2001; 12: 1228-34
53. Salusky IB, Foley J, Nelson P, et al. Aluminum accumulation during treatment with aluminum hydroxide and dialysis in children and young adults with chronic renal disease. N Engl J Med 1991; 324: 527-31
54. Molitoris BA, Froment DH, Mackenzie TA, et al. Citrate: a major factor in the toxicity of orally administered aluminum compounds. Kidney Int 1989; 36: 949-53
55. Mucsi I, Hercz G, Uldall R, et al. Control of serum phosphorus without any phosphate binders in patients treated with nocturnal hemodialysis. Kidney Int 1998; 53: 527-31
56. McCrory WW, Gertner JM, Burke FM, et al. Effects of dietary phosphate restriction in children with chronic renal failure. J Pediatr 1987; 111 (3): 410-2
57. Andreoli SP, Bergstein JM, Sherrard DJ. Aluminum intoxication from aluminum-containing phosphate binders in children with azotemia not undergoing dialysis. N Engl J Med 1984; 310 (17): 1079-84
58. Coburn JW, Norris KC. Diagnosis of aluminum-related bone disease and treatment of aluminum toxicity with deferoxamine. Semin Nephrol 1986; 6 (4 Suppl. 1): 12-21
59. Schaefer K, Scheer J, Asmus G, et al. The treatment of uremic hyperphosphatemia with calcium acetate and calcium carbonate: a comparative study. Nephrol Dial Transplant 1991; 6: 170-5
60. Indridason OS, Quarles LD. Comparison of treatments for mild secondary hyperparathyroidism in hemodialysis patients. Durham Renal Osteodystrophy Study Group. Kidney Int 2000; 57 (1): 282-92
61. Goodman WG, Ramirez JA, Belin TR, et al. Development of adynamic bone in patients with secondary hyperparathyroidism after intermittent calcitriol therapy. Kidney Int 1994; 46: 1160-6
62. Andreoli SP, Dunson JW, Bergstein JM. Calcium carbonate is an effective phosphorus binder in children with chronic renal failure. Am J Kidney Dis 1987; 9 (3): 206-10
63. Block GA. Prevalence and clinical consequences of elevated Ca x P product in hemodialysis patients. Clin Nephrol 2000; 54 (4): 318-24
64. Goodman WG, Goldin J, Kuizon B, et al. Coronary artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000; 342 (20): 1478-83
65. Slatopolsky EA, Burke SK, Dillon MA. RenaGel, a nonabsorbed calcium-and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone. Kidney Int 1999; 55: 299-307
66. Chertow GM, Burke SK, Dillon MA, et al. Long-term effects of sevelamer hydrochloride on the calcium x phosphate product and lipid profile of hemodialysis patients. Nephrol Dial Transplant 1999; 14: 2907-14
67. Chertow GM, Burke SK, Lazarus JM, et al. Poly[allylamine hydrochloride] (RenaGel): a noncalcemic phosphate binder for the treatment of hyperphosphatemia in chronic renal failure. Am J Kidney Dis 1997; 29 (1): 66-71
68. Hergesell O, Ritz E. Stabilized polynuclear iron hydroxide is an efficient oral phosphate binder in uraemic patients. Nephrol Dial Transplant 1999; 14: 863-7
69. Hsu CH, Patel SR, Young EW. New phosphate binding agents: ferric compounds. J Am Soc Nephrol 1999; 10 (6): 1274-80
70. Delmez JA, Kelber J, Norword KY, et al. Magnesium carbonate as a phosphate binder: a prospective, controlled, cross-over study. Kidney Int 1996; 49: 163-7
71. Joy MS, Finn WF, Randomized, double-blind, placebo-controlled, dose-titration, phase III study assessing the efficacy and tolerability of lanthanum carbonate: a new phosphate binder for the treatment of hyperphosphatemia. Am J Kidney Dis 2003; 42(1): 96-107
72. Cannella G, Bonucci E, Rolla D, et al. Evidence of healing of secondary hyperparathyroidism in chronically hemodialyzed uremic patients treated with long-term intravenous calcitriol. Kidney Int 1994; 46: 1124-32
73. Delmez JA, Dougan CS, Gearing BK, et al. The effects of intraperitoneal calcitriol on calcium and parathyroid hormone. Kidney Int 1987; 31: 795-9
74. Dunlay R, Rodriguez M, Felsenfeld AJ, et al. Direct inhibitory effect of calcitriol on parathyroid function (sigmoidal curve) in dialysis. Kidney Int 1989; 36: 1093-8
75. Moe SM, Kraus MA, Gassensmith CM, et al. Safety and efficacy of pulse and daily calcitriol in patients on CAPD: a randomized trial. Nephrol Dial Transplant 1998; 13: 1234-41
76. 3 and 22-oxacalcitriol prevent the decrease in vitamin D receptor content in the parathyroid glands of uremic rats. Kidney Int 1996; 50: 34-9
77. 3 in the parathyroid in vivo. J Clin Invest 1990; 86: 1968-75
78. Henderson RG, Ledingham JGG, Oliver DO, et al. Effects of 1,25-dihydrocholecalciferol on calcium absorption, muscle weakness, and bone disease in chronic renal failure. Lancet 1974; I (7854): 379-84
79. 3 on calcium absorption and bone resorption in man. Lancet 1974 Mar; I (7854): 385-9
80. 3 in childhood renal osteodystrophy. N Engl J Med 1978; 298: 238-42
81. 3 on renal function, mineral balance, and growth in children with severe chronic renal failure. Pediatrics 1981; 68 (4): 559-71
82. Hymes LC, Warshaw BL. Vitamin D replacement therapy and renal function. Am J Dis Child 1984; 138: 1125-8
83. Kanis JA. The use of alfacalcidol in the prevention of bone disease in early renal failure. Nephrol Dial Transplant 1995; 10 Suppl. 4: 23-8
84. 3 (calcifediol) therapy of juvenile renal osteodystrophy: beneficial effect on linear growth velocity. J Pediatr 1982; 100 (5): 815-20
85. Trachtman H, Gauthier B. Parenteral calcitriol for treatment of severe renal osteodystrophy in children with chronic renal insufficiency. J Pediatr 1987; 110: 966-70
86. Eke FU, Winterborn MH. Effect of low dose 1α- hydroxycholecalciferol on glomerular filtration rate in moderate renal failure. Arch Dis Child 1983; 58: 810-3
87. Christiansen C, Rodbro P, Christensen MS, et al. Is 1,25-dihydroxy- cholecalciferol harmful to renal function in patients with chronic renal failure? Clin Endocrinol 1981; 15: 229-36
88. Tougaard L, Sorensen E, Brochner-Mortensen J, et al. Controlled trial of 1α-hydrocholecalciferol in chronic renal failure. Lancet 1976; I: 1044-7
89. Ardissino G, Schmitt CP, Testa S, et al. Calcitriol pulse therapy is not more effective than daily calcitriol therapy in controlling secondary hyperparathyroidism in children with chronic renal failure. Pediatr Nephrol 2000; 14 (7): 664-8
90. Bianchi ML, Colantonio G. Campanini F, et al. Calcitriol and calcium carbonate therapy in early chronic renal failure. Nephrol Dial Transplant 1994; 9: 1595-9
91. Ritz E, Kuster S, Schmidt-Gayk H, et al. Low-dose calcitriol prevents the rise in 1,84 iPTH without affecting serum calcium and phosphate in patients with moderate renal failure (prospective placebo-controlled multicentre trial). Nephrol Dial Transplant 1995; 10: 2228-34
92. 3 administration in moderate renal failure: a prospective double-blind trial. Kidney Int 1989; 35: 661-9
93. 3: humoral and histomorphometric results. Miner Electrolyte Metab 1986; 12: 375-82
94. Nordal KP, Dahl E. Low dose calcitriol versus placebo in patients with predialysis chronic renal failure. J Clin Endocrinol Metab 1988; 67 (5): 929-36
95. 3 treatment of nondialyzed patients with chronic renal failure: effects on bone, mineral metabolism and kidney function. Clin Nephrol 1980; 13 (3): 103-8
96. St John A, Thomas M, Dick I, et al. Parathyroid function in mild to moderate renal failure: evaluation by oral calcium suppression test. J Clin Endocrinol Metab 1994; 78 (6): 1436-8
97. 2, suppresses parathyroid hormone secretion in uremic rats in the absence of hypercalcemia. Am J Kidney Dis 1995; 26 (5): 852-60
98. Slatopolsky E, Weerts C, Thielan J, et al. Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxycholecalciferol in uremic patients. J Clin Invest 1984; 74: 2136-43
99. Potter DE, Wilson CJ, Ozonoff MB. Hyperparathyroid bone disease in children undergoing long-term hemodialysis; treatment with vitamin D. J Pediatr 1974; 85 (1): 60-6
100. Paunier L, Salusky IB, Slatopolsky E, et al. Renal osteodytsrophy in children undergoing continuous ambulatory peritoneal dialysis. Pediatr Res 1984; 18 (8): 742-7
101. Hodson EM, Evans RA, Dunstan CR, et al. Treatment of childhood renal osteodystrophy with calcitriol or ergocalciferol. Clin Nephrol 1985; 24 (4): 192-200
102. Hewitt IK, Stefanidis C, Reilly BJ, et al. Renal osteodystrophy in children undergoing continuous ambulatory peritoneal dialysis. J Pediatr 1983; 103: 729-34
103. Salusky IB, Coburn JW, Brill J, et al. Bone disease in pediatric patients undergoing dialysis with CAPD or CCPD. Kidney Int 1988; 33: 975-82
104. 3 therapy in children treated with peritoneal dialysis. Clin Nephrol 1994; 42 (1): 44-9
105. Witmer G, Margolis A, Fontaine O, et al. Effects of 25- hydroxycholecalciferol on bone lesions of children with terminal renal failure. Kidney Int 1976; 10: 395-408
106. Salusky IB, Kuizon BD, Belin TR, et al. Intermittent calcitriol therapy in secondary hyperparathyroidism: a comparison between oral and intraperitoneal administration. Kidney Int 1998; 54 (3); 907-14
107. Kuizon BD, Goodman WG, Juppner H, et al. Diminished linear growth during intermittent calcitriol therapy in children undergoing CCPD. Kidney Int 1998; 53: 205-11
108. Schmitt CP, Ardissino G, Testa S, et al. Growth in children with chronic renal failure on intermittent versus daily calcitriol. Pediatr Nephrol 2003; 18: 440-4
109. 3 supplements. Am J Nephrol 1999; 19: 428-32
110. Delmez JA, Kelber J, Norwood KY, et al. A controlled trial of early treatment of secondary hyperparathyroidism with calcitriol in hemodialysis patients. Clin Nephrol 2000; 54(4): 301-8
111. Quarles LD, Yohay DA, Carroll BA, et al. Prospective trial of pulse oral versus intravenous calcitriol treatment of hyperparathyroidism in ESRD. Kidney Int 1994; 45: 1710-21
112. Tsukamoto Y, Hanaoka M, Matsuo T, et al. Effect of 22-oxacalcitriol on bone histology of hemodialyzed patients with severe secondary hyperparathyroidism. Am J Kidney Dis 2000; 35 (3): 458-64
113. 3 on parathyroid gland function in haemodialysis patients with secondary hyperparathyroidism. Nephrol Dial Transplant 2002; 17 Suppl. 10: 20-7
114. 2 (paracalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis. J Am Soc Nephrol 1998; 9: 1427-32
115. 2 in hemodialysis patients with moderate to severe secondary hyperparathyroidism. Kidney Int 1997; 51: 317-23
116. 2) therapy for secondary hyperparathyroidism. Am J Kidney Dis 2000; 36(3): 550-61
117. Ishii H, Wada M, Furuya Y, et al. Daily intermittent decreases in serum levels of parathyroid hormone have an anabolic-like action on the bones of uremic rats with low-turnover bone and osteomalacia. Bone 2000; 26 (2): 175-82
118. Lane NE, Sanchez S, Modin GW, et al. Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis: results of a randomized controlled clinical trial. J Clin Invest 1998; 102: 1627-33
119. Schmitt CP, Hessing S, Oh J, et al. Intermittent administration of parathyroid hormone (1-37) improves growth and bone mineral density in uremic rats. Kidney Int 2000; 57 (4): 1484-92
120. Lindberg JS, Moe SM, Goodman WG, et al. The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidism. Kidney Int 2003; 63 (1): 248-54
121. Goodman WG, Hladik GA, Turner SA, et al. The calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism. J Am Soc Nephrol 2002; 13 (4): 1017-24
122. Chang W, Tu C, Chen T-H, et al. Expression and signal transduction of calcium-sensing receptors in cartilage and bone. Endocrinology 1999; 140 (12): 5883-93
123. Kakuta T, Fukagawa M, Fujisaki T, et al. Prognosis of parathyroid function after successful percutaneous ethanol injection therapy guided by color doppler flow mapping in chronic dialysis patients. Am J Kidney Dis 1999; 33 (6): 1091-9
124. Kitaoka M, Fukagawa M, Ogata E, et al. Reduction of functioning parathyroid cell mass by ethanol injection in chronic dialysis patients. Kidney Int 1994; 46: 1110-7